Clinical Trial Update: Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial CHIME 2 evaluating treatment for impulsive aggression in subjects with ADHD, completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Status: COMPLETED | Results posted: 2024-03-18